GoodRx announced Thursday morning that it is working with Sanofi on a program to offer one of its leading insulin products to consumers for $35 per month.
By visiting GoodRx.com/lantus, patients can access a $35 price coupon for a 30-day supply of Sanofi’s Lantus (insulin glargine injection) 100 Units/mL. The coupons can be redeemed at the 70,000 pharmacies nationwide that accept GoodRx, including leading retailers like CVS, Walgreens and Walmart.
The company specified that patients will be able to use the coupon regardless of their health insurance coverage.
The announcement comes more than six months after Sanofi pledged to slash the list price of Lantus, establishing a $35 cap on out-of-pocket costs for the treatment for patients living with diabetes that have commercial insurance.
Sanofi expanded its savings program to offer Lantus for $35 to people without insurance and also cut the list price of its short-acting Apidra by 70%.
Sanofi joined Novo Nordisk and Eli Lilly in capping costs of insulin used by patients with diabetes following the passage of the Inflation Reduction Act last summer, which capped the monthly price of insulin at $35 for Medicare beneficiaries.
Subsequently, President Biden called for a universal price cap during his State of the Union address in February.
“Efforts to make insulin more accessible have been at the forefront of the news for months, and a critical piece of delivering on this promise is making it as simple as possible for patients to get the lower price right at their regular pharmacy counter,” Dorothy Gemmell, chief commercial officer at GoodRx, said in a statement. “Sanofi is taking action and providing Americans who need insulin with the ability to access Lantus in an easy and affordable way, regardless of insurance status. We’re proud to collaborate with them on this initiative.”
Of note, Sanofi CEO Paul Hudson testified in front of the Senate Health, Education, Labor and Pensions committee during the spring as part of a hearing dedicated to the role manufacturers have in dictating insulin prices.
The French drugmaker reiterated in a statement that “no one should struggle to pay” for their insulin and that it welcomed the opportunity to collaborate with GoodRx on the initiative.
For years, GoodRx has worked with several large pharmaceutical manufacturers through its Pharma Manufacturer Solutions offering. The company even recently teamed up with CVS Health’s pharmacy benefit manager, CVS Caremark.
As part of that partnership, the two companies launched the Caremark Cost Saver to give CVS Caremark members the ability to access GoodRx’s prescription pricing capabilities starting January 1, 2024.
